Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We thank Feghali et al and Rezai et al for their interest in our article.1 They raise important considerations when interpreting our results. We acknowledge that our measure for obesity is imperfect and that there is the potential for residual confounding. Previous literature has shown that neonatal risk increases gradually with higher maternal weight, and this may also be the case among pharmacologically treated women.2 In light of the inherent heterogeneity among women initiating pharmacological treatment, we need to better understand whether the increased risk for women treated with glyburide (compared with insulin) varies by maternal weight.
Castillo WC, Funk MJ. Glyburide vs Insulin and Adverse Pregnancy Outcomes—Reply. JAMA Pediatr. 2015;169(10):975. doi:10.1001/jamapediatrics.2015.1811